-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-547 in Uremic (Renal) Pruritus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Uremic (Renal) Pruritus Drug Details: EP-547 is under developmant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Hepatitis B
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Hepatitis B Drug Details: EP-547 is under developmant for the treatment of cholestatic pruritus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-262 in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-262 in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-262 in Chronic Urticaria Or Hives Drug Details: EP-262 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-262 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-262 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-262 in Atopic Dermatitis (Atopic Eczema) Drug Details: EP-262 is...
-
Product Insights
EP Newington Combined Cycle Power Plant
EP Newington Combined Cycle Power Plant is a thermal project located in New Hampshire, United States. The project is owned by Nautilus Power LLC. The project came online in 2002. Empower your strategies with our EP Newington Combined Cycle Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Company Insights
Innovation and Patenting activity of EPS Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of EPS Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-282 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-282 in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-282 in Inflammation Drug Details: EP-282 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Pruritus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Pruritus Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to primary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-282 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-282 in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EP-282 in Inflammation Drug Details:EP-282 is under development for the treatment of intestinal infection,...